– Industry veteran brings extensive clinical development experience to AVEO Oncology leadership team as Chief Medical Officer –

–作为首席医疗官，行业资深人士为AVEO肿瘤学领导团队带来了丰富的临床开发经验–

– Formation of a Scientific Advisory Committee from world-renowned cancer institutions –

–由世界知名癌症机构组成科学咨询委员会–

BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.) (“AVEO”), an LG Chem company, today announced the appointment of Edgar E. Braendle, MD, PhD as AVEO Oncology’s new Chief Medical Officer. Dr. Braendle is a life sciences executive with experience spanning from early drug discovery to the launch of small molecules, biologics, radiopharmaceuticals, gene and cell therapies, and medical device development..

波士顿，2024年3月25日（环球通讯社）--LG化学公司AVEO Oncology（也称为AVEO Pharmaceuticals，Inc.）（“AVEO”）今天宣布任命Edgar E.Braendle博士为AVEO Oncology的新任首席医疗官。Braendle博士是一名生命科学高管，拥有从早期药物发现到小分子、生物制剂、放射性药物、基因和细胞疗法以及医疗器械开发的丰富经验。。

Dr. Braendle brings more than twenty years of clinical research experience to AVEO Oncology, most recently serving as Chief Development Officer of Autolus Therapeutics Plc since July 2021, where he was responsible for all development functions and the conduct of the pivotal program of AUCATZYL™ (a CD-19 directed genetically modified autologous T cell immunotherapy) in adult acute lymphoblastic leukemia, and the respective filing to the U.S.

Braendle博士为AVEO Oncology带来了20多年的临床研究经验，最近自2021年7月起担任Autolus Therapeutics Plc的首席开发官，负责成人急性淋巴细胞白血病的所有开发功能和AUCATZYL™（CD-19定向基因修饰自体T细胞免疫疗法）关键项目的实施，并分别提交给美国。

Food & Drug Administration and European Medicines Agency.   .

食品和药物管理局和欧洲药品管理局。。

“We are delighted to have Dr. Braendle join the AVEO Oncology team particularly at this important juncture as we seek to become a global top 20 oncology leader,” said Michael P. Bailey, President and Chief Executive Officer of AVEO Oncology, an LG Chem company. “Dr. Braendle’s significant experience will be instrumental in our efforts to develop and diversify our pipeline.”.

LG化学公司AVEO Oncology总裁兼首席执行官迈克尔·贝利（MichaelP.Bailey）表示：“我们很高兴Braendle博士加入AVEO肿瘤学团队，特别是在我们寻求成为全球20强肿瘤学领导者的这一重要时刻。”。“Braendle博士的丰富经验将有助于我们努力开发和多样化我们的管道。”。

Prior to his time at Autolus, Dr. Braendle held the role of Executive Vice President, Chief Medical Officer and Global Head of Development at Sumitomo Dainippon Pharma Oncology, where he was responsible for a full range of development functions and progressed several early-stage, first in human programs and late-stage programs.

在加入Autolus之前，Braendle博士曾担任住友大尼蓬制药肿瘤学公司的执行副总裁、首席医疗官和全球开发主管，负责全方位的开发功能，并在几个早期阶段取得了进展，包括人类项目和晚期项目。

Prior to this, Dr. Braendle served as President and CEO of ARUP Laboratories, a national clinical and anatomic reference laboratory. Dr. Braendle also spent over a decade at Novartis AG, where he served as Senior Vice President and Global Head of Companion Diagnostics and led the company's precision medicine approach.

在此之前，Braendle博士担任国家临床和解剖学参考实验室ARUP实验室的总裁兼首席执行官。Braendle博士还在诺华公司工作了十多年，担任高级副总裁兼Companion Diagnostics全球负责人，并领导该公司的精准医学方法。

Dr. Braendle received his medical degree at RWTH Aachen University in Germany, followed by specialty training in medical oncology, urology and pharmacology. Dr. Braendle is also an associate professor at the University of Ulm, Germany..

Braendle博士在德国亚琛RWTH大学获得了医学学位，随后接受了医学肿瘤学，泌尿学和药理学的专业培训。Braendle博士也是德国乌尔姆大学的副教授。。

Today, AVEO Oncology, an LG Chem company, and LG Chem Life Sciences also announced the formation of its Scientific Advisory Committee (“Committee”). This esteemed group of experts in oncology research and clinical development were selected to advise and bring unique perspectives to AVEO and LG Chem’s clinical strategy and business development initiatives.

今天，LG化学公司AVEO Oncology和LG化学生命科学公司也宣布成立其科学咨询委员会（“委员会”）。这个备受尊敬的肿瘤学研究和临床开发专家组被选中，为AVEO和LG Chem的临床战略和业务发展计划提供建议并带来独特的观点。

'We are excited and privileged to have the opportunity to work with this group of top oncology experts to help guide our drug development initiatives from discovery through commercialization. Notably, the Committee represents key areas of interest including gastrointestinal, genitourinary, ovarian, lung and head and neck cancers,' said Mr.

“我们很高兴和荣幸有机会与这组顶级肿瘤学专家合作，帮助指导我们的药物开发计划，从发现到商业化。值得注意的是，该委员会代表了人们感兴趣的关键领域，包括胃肠道癌、泌尿生殖道癌、卵巢癌、肺癌和头颈癌。

Bailey..

贝利。。

The Scientific Advisory Committee is comprised of several leading cancer experts, including:

科学咨询委员会由几位顶尖的癌症专家组成，其中包括：

Al B. Benson III, MD, FACP, FACCC, FASCO

Al B.Benson III，医学博士，FACP，FACCC，FASCO

Professor of Medicine

医学教授

Associate Director from Cooperative Groups

合作小组副主任

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

西北大学罗伯特·H·卢里综合癌症中心

Scott Kopetz, MD, PhD

斯科特·科佩茨，医学博士，博士

Professor and Deputy Chair for Translational Research, Department of Gastrointestinal Medical Oncology

胃肠内科肿瘤学教授兼转化研究副主席

Division of Cancer Medicine

癌症医学部

University of Texas MD Anderson Cancer Center

德克萨斯大学安德森癌症中心

D. Ross Camidge, MD, PhD

D.Ross Camidge，医学博士、博士

Professor of Medicine/ Oncology

医学/肿瘤学教授

Joyce Zeff Chair in Lung Cancer

Joyce Zeff肺癌治疗椅

Director, Thoracic Oncology

胸肿瘤科主任

Faculty, Developmental Therapeutics Program

发展治疗学课程教员

University of Colorado Cancer Center, Aurora

科罗拉多大学癌症中心，奥罗拉

John L. Marshall, MD

医学博士John L.Marshall

Chief, Hematology and Oncology

血液学和肿瘤学主任

Professor of Medicine and Oncology

医学与肿瘤学教授

Director, Otto J Ruesch Center for the Cure of Gastrointestinal Cancers Georgetown Lombardi Comprehensive Cancer Center

乔治敦-伦巴第综合癌症中心胃肠道癌症治疗中心主任

Edward Chu, MD, MMS

Edward Chu，医学博士，MMS

Director, Montefiore Einstein Cancer Center

Montefiore Einstein癌症中心主任

Albert Einstein College of Medicine

爱因斯坦医学院

Tony S.K. Mok, BBS, FASCO

Tony S.K.Mok，BBS，FASCO

Chairman, Department of Clinical Oncology

临床肿瘤学系主任

LiShu Fan Professor of Clinical Oncology

范丽淑临床肿瘤学教授

The Chinese University of Hong Kong

香港中文大学

Ezra Cohen, MD, FRCPSC, FASCO

埃兹拉·科恩，医学博士，FRCPSC，FASCO

Chief Medical Officer of Oncology

肿瘤学首席医疗官

Tempus

时间

University of California- San Diego

加利福尼亚大学圣地亚哥分校

Paul G. Richardson, MD

医学博士Paul G.Richardson

Director, Clinical Research

临床研究主任

Jerome Lipper Multiple Myeloma Center

杰罗姆·利珀多发性骨髓瘤中心

Dana-Farber Cancer Institute

达纳法伯癌症研究所

Kevin J. Cullen, MD

Kevin J.Cullen，医学博士

Professor of Oncology

肿瘤学教授

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

马里兰大学马琳和斯图尔特·格林鲍姆综合癌症中心

University of Maryland School of Medicine

马里兰大学医学院

Joseph Tabernero, MD, PhD

Joseph Tabernero，医学博士、博士

Head, Medical Oncology Department

肿瘤内科主任

Director, Vall d’Hebron Institute of Oncology

瓦尔德希布伦肿瘤研究所所长

Professor of Medicine, UVic-UCC

UVic UCC医学教授

Enrique Grande, MD, PhD, Msc

Enrique Grande，医学博士、博士、硕士

Director, Medical Oncology Program and Clinical Research lead

医学肿瘤学项目主任和临床研究负责人

MD Anderson Cancer Center Madrid

MD安德森癌症中心马德里

Jan Vermorken, MD, PhD

Jan Vermorken，医学博士、博士

Emeritus Professor of Oncology

肿瘤学名誉教授

Department of Medical Oncology

肿瘤内科

Antwerp University Hospital

安特卫普大学医院

For more information about the Scientific Advisory Committee, please visit https://www.aveooncology.com/about/scientific-advisory-committee/.

有关科学咨询委员会的更多信息，请访问https://www.aveooncology.com/about/scientific-advisory-committee/.

About AVEO Pharmaceuticals, Inc.

关于AVEO Pharmaceuticals，股份有限公司。

AVEO is an oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies.

AVEO是一家专注于肿瘤学的生物制药公司，致力于为癌症患者提供更好生活的药物。AVEO目前在美国销售FOTIVDA®（tivozanib），用于治疗两种或两种以上先前全身治疗后复发或难治性肾细胞癌（RCC）的成年患者。

AVEO continues to develop FOTIVDA in immunooncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO became a wholly owned subsidiary of LG Chem Life Sciences USA, Inc. on January 19, 2023. AVEO continues to operate under the AVEO Oncology, an LG Chem company, name.

AVEO继续在免疫肿瘤学和RCC和其他适应症中的其他新型靶向组合中开发FOTIVDA，并在临床开发中拥有其他研究计划。2023年1月19日，AVEO成为LG Chem Life Sciences USA，Inc.的全资子公司。AVEO继续在LG化学公司AVEO Oncology旗下运营。

For more information, please visit www.aveooncology.com..

有关更多信息，请访问www.aveooncology.com。。

About LG Chem, Ltd. and LG Chem Life Sciences

关于LG Chem，Ltd.和LG Chem Life Sciences

LG Chem, Ltd. (LG Chem) is a leading global chemical company with a diversified business portfolio in the key areas of petrochemicals, advanced materials, and life sciences. The company manufactures a wide range of products from high-value added petrochemicals to renewable plastics, specializing in cutting-edge electronic and battery materials, as well as drugs and vaccines to deliver differentiated solutions for its customers.

LG化工有限公司（LG Chem）是一家领先的全球化工公司，在石化、先进材料和生命科学等关键领域拥有多元化的业务组合。该公司生产多种产品，从高附加值的石化产品到可再生塑料，专门生产尖端电子和电池材料，以及药物和疫苗，为客户提供差异化的解决方案。

LG Chem Life Sciences develops, manufactures, and globally commercializes pharmaceutical products, with a focus on Oncology, Immunology, and Metabolic diseases. Our mission is to transform people’s lives through inspiring science and leading innovation. For more information, please visit www.lgchem.com..

LG Chem Life Sciences开发、制造和全球商业化医药产品，重点关注肿瘤学、免疫学和代谢疾病。我们的使命是通过激励科学和领导创新来改变人们的生活。有关更多信息，请访问www.lgchem.com。。

ContactsMedia:

联系方式：

John F. Kouten

约翰·F·库滕

JFK Communications, Inc.

肯尼迪通信公司。

jfkouten@jfkhealth.com

jfkouten@jfkhealth.com

(908) 227-4714

(908) 227-4714

Source: AVEO Pharmaceuticals, Inc.

资料来源：AVEO Pharmaceuticals，股份有限公司。